Building an AI Center of Excellence on a $2M Budget: A Mid-Cap Pharma Approach

The Mid-Cap Context: What Differs From Large-Cap

Mid-cap pharma differs from large-cap pharma in several ways that materially shape AI strategy. Understanding the differences is the starting point for building a CoE that fits the context rather than aspiring to large-cap configurations the budget cannot sustain.

Resource constraints. A large-cap pharma might invest $50M-$200M annually in AI across the enterprise. A mid-cap typically operates with $5M-$20M. The CoE’s share of that budget is necessarily smaller in absolute terms, and the CoE has to be designed around the constraint, not in spite of it.

Talent market disadvantage. Mid-cap pharma competes for AI talent against large-cap pharma, technology companies, and well-funded AI-native biotechs. The talent market disadvantage is real and shapes the staffing model: the CoE typically cannot afford to staff at the level large-cap competitors do and has to compensate with focus, culture, and selective external partnerships.

Portfolio scope. Mid-cap pharma typically has fewer therapeutic areas and a narrower pipeline than large-cap. The AI portfolio should reflect this; the CoE can credibly focus its work on a smaller number of high-leverage use cases, while large-cap CoEs spread across more diverse opportunity surfaces.

Regulatory and quality function size. Mid-cap regulatory and quality functions are smaller, which produces both constraint (less capacity to support AI initiatives) and opportunity (closer integration possible between AI work and the regulatory function).

Cross-functional dynamics. In mid-cap pharma, executives are typically closer to the day-to-day work and to each other. The CoE can build cross-functional working relationships more rapidly than in large-cap organizations, where the formal coordination structure is heavier.

These differences mean that the mid-cap CoE is not a smaller version of the large-cap CoE. It is a different organizational pattern, designed around the constraints and opportunities specific to mid-cap pharma. As described in Prommer’s analysis of the Gartner AI maturity model, mid-market companies typically sit at the “Opportunistic” level of maturity, and the transition to “Systematic” looks like AI recognized as a strategic priority with dedicated resources, a center of excellence, and cross-functional governance. The CoE is the operational expression of this transition.

What $2M Actually Buys

The $2M budget envelope, distributed thoughtfully, can sustain a meaningful CoE. The allocation we recommend, based on engagements with mid-cap pharma clients:

The allocation is calibrated to what actually produces value at the scale, not to what an ideal allocation would look like in a budget-unconstrained environment. Several allocations are deliberately conservative:

Technology and tooling at 20%. Large-cap CoEs often spend more on technology, but mid-cap CoEs benefit from buying access to capabilities through SaaS rather than building custom infrastructure. The 20% allocation funds a meaningful tooling stack without overcommitting to platform investments that the CoE cannot sustain.

External partnerships at 12.5%. External partnerships are essential for mid-cap CoEs because internal capability development takes time. The partnership budget funds the consultants, the vendor professional services, and the academic collaborations that fill capability gaps during the build phase.

Experimentation reserve at 2.5%. The reserve is small but matters. Without dedicated experimentation funding, every pilot has to be justified through normal budget cycles, which produces friction. The reserve allows the CoE to spin up small experiments rapidly when the strategic opportunity is clear but the formal business case has not yet been built.

The compensation envelope for core staffing — $240K-$300K loaded cost per FTE on average — is competitive for mid-cap pharma markets but not aspirational for top-tier AI talent. The implication is that the staffing model has to optimize for fit and motivation rather than for top-of-market hire.

The Staffing Model That Works at This Scale

The 4-5 FTE staffing envelope requires careful role design. The model we recommend:

Head of CoE. Senior leader with pharma domain experience and meaningful AI exposure. Reports to a member of the executive committee — typically CIO, Chief Digital Officer, or Chief Scientific Officer depending on the mandate. The Head of CoE is the strategic leader, the relationship owner, and the voice to the executive committee. Compensation toward the top of the envelope.

Principal AI Engineer / Architect. Senior technical leader with deep AI/ML experience and pharma awareness. Owns the technology stack decisions, the production-grade implementation patterns, and the technical mentorship of the rest of the team. The Principal is the technical authority that the rest of the organization trusts.

AI Product Manager. Translates business problems into AI use cases, manages the use case portfolio, owns the value tracking. The Product Manager is the bridge between the CoE and the business functions whose problems the CoE is trying to solve.

AI Quality and Governance Lead. Owns the governance framework, the validation discipline, the regulatory engagement, and the documentation that makes the CoE’s work defensible. The role is more important in pharma than in horizontal CoEs and consumes more capacity than most leaders initially budget for.

Optional fifth FTE: AI Engineer or Data Scientist. A more junior technical contributor who executes against the architecture and product direction. The fifth role gives the CoE meaningful execution capacity beyond what the principal alone can produce. Some configurations skip this role and use external partnership budget to fill execution capacity instead.

The staffing model deliberately avoids configurations that mid-cap budgets cannot sustain — for example, separate research and engineering teams, dedicated specialist roles for narrow capabilities, or large junior teams. The compactness is a feature: the team can meet in a single conversation, decisions move quickly, and accountability is clear.

Scope Decisions: What the CoE Should and Should Not Do

The scope of the CoE is the strategic decision that determines whether the $2M produces real value. Mid-cap CoEs cannot do everything large-cap CoEs do; the scope decisions force the prioritization.

What the CoE should do:

• Strategy and prioritization. The portfolio view of AI initiatives, the prioritization framework, and the resource allocation guidance for the executive committee.
• Governance and standards. The risk classification, the validation framework, the documentation patterns, and the cross-functional governance.
• Reusable platform components. The handful of platform investments (model access, observability, governance tooling) that the CoE provides as shared services to use case teams.
• First-deployment partnership. Deep engagement with the first 2-3 use case teams in each major function, transferring capability and patterns that subsequent teams can reuse.
• External relationship management. Vendor management, partnership cultivation, regulatory engagement on AI topics.

What the CoE should not do:

• Execute every AI use case. The CoE does not have the capacity to be the production team for every AI deployment. Use cases execute in their owning functions; the CoE supports.
• Build custom foundation models. The economics do not work at mid-cap scale; the CoE uses commercial foundation models and focuses its technical investment elsewhere.
• Operate as the AI use case approval body. The governance committee, not the CoE alone, makes use case decisions. The CoE provides the framework and the evidence.
• Conduct primary research. Mid-cap CoEs typically cannot sustain research investment; they focus on applied work and rely on academic and vendor research for advances.

The scope discipline produces a CoE that does fewer things, does them well, and is sustainable at the budget envelope. Scope expansion temptations are constant — every function has an AI use case it wants the CoE to lead — and the discipline of declining is what preserves the CoE’s value.

The Technology Stack on a Mid-Cap Budget

The technology stack on a mid-cap budget emphasizes commercial SaaS, judicious open-source, and aggressive vendor consolidation. The pattern we recommend:

Foundation model access. Commercial API access to one or two foundation model families, with appropriate enterprise terms (data handling, model version stability, validation cooperation). Private deployment becomes economic only at higher utilization than mid-cap CoEs typically reach in the first two years.

Development platform. A unified development platform — typically a major hyperscaler’s AI/ML offering — that combines compute, model hosting, observability, and governance. Multi-cloud is operationally expensive at mid-cap scale and rarely justifies the complexity.

Data quality and observability. A modern data quality tool (Ataccama, or for observability-led approaches, Monte Carlo or Acceldata) that supports both the CoE’s work and the broader data governance discipline. The tool selection should be made carefully because mid-cap budgets cannot easily support tool churn.

Governance and documentation. A combination of formal governance tooling and SharePoint/Confluence-grade documentation infrastructure. Sophisticated governance platforms are expensive and often over-featured for mid-cap CoEs; documentation discipline matters more than tooling.

Experimentation environment. A bounded environment where SMEs and use case teams can run experiments without engaging the CoE for every iteration. The environment is meaningful for CoE leverage: it lets the CoE provide capability without becoming a bottleneck.

The technology stack should be designed for steady-state operation at the budget envelope, not for the upside case. Stacks designed around the upside case typically include line items that the budget cannot sustain in down years, producing painful retrenchment when budget pressure arrives.

Governance and Cross-Functional Integration

The CoE’s value depends on its integration with the rest of the organization. Several governance patterns produce that integration.

AI Steering Committee. Cross-functional, chaired by an executive sponsor, with representation from the major functions and from QA/Regulatory. The committee makes portfolio-level decisions; the CoE provides the evidence and recommendations.

Function-level AI champions. Designated individuals in each major function who serve as the liaison between the function and the CoE. The champions are not full-time CoE staff; they are subject matter experts in their function with formal coordination responsibility.

Tiered risk classification. The classification framework that maps use cases to governance expectations. The same framework large-cap CoEs use, adapted to mid-cap scale: fewer tiers, less elaborate review processes, but the same risk-based logic.

Quarterly portfolio review. A formal review cadence where the steering committee evaluates the AI portfolio, makes prioritization decisions, and allocates the experimentation reserve. The cadence is the operational rhythm of the CoE’s work.

Annual strategy refresh. A full strategy review that recalibrates the CoE’s priorities, scope, and resource allocation. The annual refresh prevents drift and maintains alignment with the broader corporate strategy.

The 18-Month Roadmap and Milestones

The first 18 months of a mid-cap pharma CoE follow a recognizable arc. The roadmap we recommend:

Months 1-3: Foundation. Recruit core staffing, establish governance, complete AI inventory, identify first signature initiatives, build the steering committee. The phase delivers structural foundation rather than visible value.

Months 4-9: First deployments. Execute the first 2-3 signature initiatives in partnership with use case teams. Establish the validation patterns, the documentation discipline, and the lessons-learned cadence. The phase produces the visible value that justifies continued investment.

Months 10-15: Capability expansion. Build the platform components, harden the governance, transfer patterns to subsequent use case teams, and broaden the AI literacy across the organization. The phase produces leverage: the CoE’s contribution to each subsequent use case decreases as the patterns become reusable.

Months 16-18: Strategic reset. Conduct the annual strategy refresh, evaluate the budget envelope for year two, and reset priorities based on what the first 18 months have surfaced. The reset is the input to the year-two operating plan.

Milestones we recommend tracking:

• End of Month 3: Core staffing in place, governance chartered, first signature initiatives selected
• End of Month 6: First production deployment of a signature initiative, with documented validation evidence
• End of Month 9: Two to three signature initiatives in production, lessons-learned documented and shared
• End of Month 12: Platform components in steady-state operation, first reuse of validation patterns by an independent use case team
• End of Month 15: AI literacy program deployed across the organization, function-level AI champions trained
• End of Month 18: Year-two strategy and budget approved, signature initiatives demonstrating measurable business value

The milestones are calibrated to what is achievable at the budget envelope, not to what would be possible with larger investment. Programs that set milestones beyond their capacity envelope produce credibility damage when they miss; programs that set milestones within capacity envelope produce credibility momentum when they hit.

Why the mid-cap CoE pattern works

The strategic logic for the mid-cap CoE pattern is that focus produces leverage. A large-cap CoE with $50M can afford to spread investment across many initiatives, but the cost is dilution: each initiative gets less CoE engagement, patterns develop more slowly, and the organizational change effort scales sublinearly with the budget. A mid-cap CoE with $2M has to concentrate, and the concentration produces depth that large-cap CoEs often do not achieve in any specific area.

The pattern also benefits from the relatively shorter distance between the CoE and the executive committee in mid-cap organizations. Where large-cap CoE leaders may be three or four levels below the CEO, mid-cap CoE leaders often report directly to a C-level executive. The proximity produces faster decisions, better strategic alignment, and more rapid course correction when initiatives are not producing expected value.

Where mid-cap CoEs fail

The most common failure mode for mid-cap CoEs is scope creep. The CoE is established with a focused mandate, demonstrates early success, and then accepts an expanding portfolio of responsibilities as the organization recognizes its value. The expansion outpaces the budget envelope, the CoE becomes over-extended, and the quality of the work degrades. Mid-cap CoE leaders should be specifically prepared to decline scope expansion until the budget envelope changes to accommodate it.

The second common failure mode is talent retention. Mid-cap CoEs that successfully recruit strong AI talent face retention pressure from large-cap pharma and technology companies that can outbid on compensation. Retention depends on factors beyond compensation: meaningful work, executive visibility, autonomy, and culture. Mid-cap CoE leaders who treat retention as a compensation question consistently lose talent to competitors who pay more; leaders who build the broader retention package fare materially better.

The economics of the second-year decision

One strategic dimension that deserves explicit attention is the second-year budget decision. The first-year budget is typically approved as part of the CoE establishment; the second-year budget is the first test of whether the CoE has produced enough value to justify continued investment. CoEs that go into the second-year decision without clear value evidence often face budget pressure that constrains their ability to deliver in year two. CoEs that go in with documented signature initiative value, demonstrable governance maturity, and an articulated three-year roadmap typically secure their budget and often produce budget expansion. The work in months 12-18 should be specifically calibrated to the year-two decision conversation, not to internal goals that are not visible to the budget process.

As the Stanford 2026 AI Index analysis published by Smart Data on enterprise AI scaling emphasizes, the gap between AI spending and demonstrated value is one of the principal causes of enterprise AI investment failure. Mid-cap CoEs that close the gap rapidly produce the conditions for sustained investment; those that do not face the budget pressure that ends many CoE programs before they reach maturity. The discipline of value demonstration is foundational to the mid-cap CoE pattern, not an optional add-on.

References & Sources